Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco

• Váldodahkkit: Yaowen Zhang (Dahkki), Jihane Belayachi (Dahkki), Yunkai Yang (Dahkki), Qiang Fu (Dahkki), Lance Rodewald (Dahkki), Hongling Li (Dahkki), Bing Yan (Dahkki), Ying Wang (Dahkki), Yanna Shen (Dahkki), Qian Yang (Dahkki), Weiyun Mu (Dahkki), Rong Tang (Dahkki), Chen Su (Dahkki), Tianfang Xu (Dahkki), Majdouline Obtel (Dahkki), Abdelkader Mhayi (Dahkki), Rachid Razine (Dahkki), Redouane Abouqal (Dahkki), Yuntao Zhang (Dahkki), Xiaoming Yang (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: BMC, 2022-08-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Background The Kingdom of Morocco approved BBIBP-CorV (Sinopharm) COVID-19 vaccine for emergency use on 22 January 2021 in a two-dose, three-to-four-week interval schedule. We conducted a retrospective cohort study to determine real-world BBIBP-CorV vaccine effectiveness (VE) against seriou...